Breaking News Headlines Today | Ground News

See every side of every news story

neurologylive.com image

News from neurologylive.com

Ground News rates neurologylive.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

neurologylive.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about neurologylive.com

Where is neurologylive.com located?neurologylive.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top neurologylive.com News

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease

Alzheimer's Disease · Taiwan

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease

58% Center coverage: 42 sources

TAIPEI, Oct. 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy…See the Story

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

FDA · United States

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

58% Center coverage: 24 sources

(MedPage Today) -- The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday. A pair of pyrimidine nucleosides, the doxecitine...See the Story

Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

Maryland · Maryland

Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

100% Center coverage: 1 sources

(MedPage Today) -- Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting...See the Story

Breaking News Topics Related to neurologylive.com